To determine whether COX-2 activity was affected by celecoxib treatment, PGE2 production using a PGE2-specific enzyme-linked immunosorbent assay was measured in conditioned medium collected from the breast cancer cell lines after celecoxib-treatment (20–60 μmol/l) for 48 hours. The gene discussed is PTGS2; the disease is breast cancer.